English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsElderpharmaceuticals

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Torrent sharpens focus on Indian market with Unichem’s brands – time to lock in?

      Torrent sharpens focus on Indian market with Unichem’s brands – time to lock in?

      The deal marks the fifth acquisition for Torrent. In 2014, Torrent had acquired a set of Elder brands. In the past few years it has acquired manufacturing plants from ZygPharma and Glochem industries and few brands from Novartis.

    • Hold Torrent Pharma, says Gaurang Shah

      Hold Torrent Pharma, says Gaurang Shah

      According to Gaurang Shah of Geojit BNP Paribas Financial Services, one may hold Torrent Pharma.

    • Like Divis Laboratories, Torrent Pharma: Anmol Ganjoo

      Like Divis Laboratories, Torrent Pharma: Anmol Ganjoo

      Anmol Ganjoo of JM Financial likes Divis Laboratories and Torrent Pharma from the pharma space.

    • Elder Pharma may hit Rs 121, says Rajat Bose

      Elder Pharma may hit Rs 121, says Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that Elder Pharmaceuticals may test Rs 121 and Vesuvius India may hit Rs 757-761.

    • Buy ILandFS Trans, Dishman Pharma, Elder Pharma: Agarwal

      Buy ILandFS Trans, Dishman Pharma, Elder Pharma: Agarwal

      According to Rajesh Agarwal of Eastern Financiers, one may buy ILandFS Transportation Networks (ITNL) with a target of Rs 112 and Dishman Pharmaceuticals with a target of Rs 50.

    • Bull's Eye: Buy Dishman Pharma, Dena Bank, Tech Mahindra

      Bull's Eye: Buy Dishman Pharma, Dena Bank, Tech Mahindra

      Saurabh Mittal of Swadeshi Credits advises buying Dena Bank with a target price of Rs 52 and Rolta with a target price of Rs 61.

    • Sell Elder Pharmaceuticals, advises Sudarshan Sukhani

      Sell Elder Pharmaceuticals, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends selling Elder Pharmaceuticals and advises looking at either Cipla, Dr Reddys Laboratories or Lupin.

    • Bull's Eye: Buy Titan, HDIL; sell Adani Port, Tata Chemical

      Bull's Eye: Buy Titan, HDIL; sell Adani Port, Tata Chemical

      Vishal Malkan of malkansview.com advised buying Opto Circuits for a target price of Rs 27.50 and Titan Industries for a target price of Rs 240.

    • Expect Elder Pharma to touch Rs 425-430: SP Tulsian

      Expect Elder Pharma to touch Rs 425-430: SP Tulsian

      SP Tulsian of sptulsian.com feels Elder Pharmaceuticals can move to a level of Rs 425-430 if the stake sale get fructified.

    • Exit Elder Pharmaceuticals: SP Tulsian

      Exit Elder Pharmaceuticals: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that investors holding Elder Pharmaceuticals can exit from the stock.

    • Stay invested in Elder Pharma: Pankaj Jain

      Stay invested in Elder Pharma: Pankaj Jain

      One should stay invested in Elder Pharmaceuticals, says Pankaj Jain, Director, Sunteck Wealthmax Capital Pvt Ltd. He feels that stock can test Rs 320-330.

    • Elder Pharma has target of Rs 410: Thununguntla

      Elder Pharma has target of Rs 410: Thununguntla

      Elder Pharma has target of Rs 410, says Jagannadham Thununguntla of SMC Global.

    • Bull's Eye: 12 trading picks for short-term gains

      Bull's Eye: 12 trading picks for short-term gains

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347